Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Image-Guided Whole Abdominal Radiation Therapy in Gynecologic Cancers

Aaron H Wolfson*
University of Miami Miller School of Medicine, USA
Corresponding Author : Aaron H. Wolfson
University of Miami Miller School of Medicine 1475 NW 12th Avenue
D-31 Miami, FL 33136, USA
Tel: 305-243-4210
Fax: 305-243-4363
E-mail: awolfson@med.miami.edu
Received May 04, 2013; Accepted July 15, 2013; Published July 22, 2013
Citation: Wolfson AH (2013) Image-Guided Whole Abdominal Radiation Therapy in Gynecologic Cancers. OMICS J Radiology 2:134. doi: 10.4172/2167-7964.1000134
Copyright: © 2013 Wolfson AH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The use of adjuvant Whole Abdominal Radiation Therapy (WART) in gynecologic cancers has not achieved widespread use for a variety of reasons. Several phase III trials comparing WART with adjuvant chemotherapy (CT) in both uterine and ovarian cancers have demonstrated marginal improvement in survival favoring CT over WART. However, the dose of conventionally delivered WART has been historically limited due in large part to the low threshold of normal organ tolerance in the upper abdomen associated with significant late effects of the bowel and kidneys in particular. Yet, with the advent of Image-Guided Radiation Therapy (IGRT), the possibility of dose reduction to nearby organs at risk along with the potential to increase target volume dose is now obtainable. This paper will review the current data related to IGRT WART for several different patient populations of gynecologic cancers.

Keywords

Top